haloperidol and Basal Ganglia Diseases studies

Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.

Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.

Research Excerpts

Excerpt	Relevance	Reference
"The HARPOON study will provide relevant information on the efficacy and safety of prophylactic haloperidol treatment for in-hospital delirium and its effects on relevant clinical outcomes in elderly at-risk medical and surgical patients."	9.19	Efficacy and safety of haloperidol prophylaxis for delirium prevention in older medical and surgical at-risk patients acutely admitted to hospital through the emergency department: study protocol of a multicenter, randomised, double-blind, placebo-control ( Anten, S; Bet, PM; Boelaarts, L; de Graaf, K; de Vries, OJ; Diepeveen, SH; Kamper, AM; Kramer, MH; Kuipéri, E; Lagaay, AM; Nanayakkara, PW; Pons, D; Schrijver, EJ; Siegel, A; van de Ven, PM; van Marum, RJ; van Strien, AM; Verburg, A, 2014)
"In patients with early-episode schizophrenia, aripiprazole demonstrates greater improvement than haloperidol on PANSS items related to social functioning."	9.14	Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia. ( Baker, RA; Docherty, JP; Eudicone, J; Mankoski, R; Marcus, RN; Mathew, S; McQuade, RD, 2010)
"This double-blind, placebo-controlled study investigated the efficacy and safety of intramuscular (IM) aripiprazole and IM haloperidol for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder."	9.12	Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. ( Andrezina, R; Carson, WH; Iwamoto, T; Josiassen, RC; Manos, G; Marcus, RN; Oren, DA; Stock, E, 2006)
"To compare the safety and estimate the response profile of olanzapine, a second-generation antipsychotic, to haloperidol in the treatment of delirium in the critical care setting."	9.11	Olanzapine vs haloperidol: treating delirium in a critical care setting. ( Bergeron, N; Dumont, M; Gottfried, SB; Skrobik, YK, 2004)
"The ABC-C and the Childhood Autism Rating Scale scores improved with cyproheptadine."	9.11	Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. ( Akhondzadeh, S; Amini, H; Erfani, S; Gudarzi, SS; Mohammadi, MR; Tehrani-Doost, M; Yasamy, MT, 2004)
"Patients with DSM-IV-diagnosed schizophrenia or schizoaffective disorder requiring long-term antipsychotic treatment were randomly assigned to open-label oral quetiapine or intramuscular haloperidol decanoate for 48 weeks."	9.11	Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. ( Glick, ID; Marder, SR, 2005)
"Aripiprazole is an investigational agent for treating schizophrenia that has a novel pharmacologic profile."	9.10	Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. ( Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL, 2002)
"Subjects (N=24) who met DSM-IV criteria for schizophrenia were randomly assigned to 6 weeks of double-blind treatment with either olanzapine, 7."	9.10	Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. ( Booij, J; de Haan, L; Dingemans, PM; Lavalaye, J; Linszen, D; van Bruggen, M, 2003)
" haloperidol during the first 24 hours of treatment of acute schizophrenia."	9.10	Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. ( Alaka, K; Battaglia, J; Birkett, M; Bitter, I; Breier, A; Chouinard, G; Ferchland-Howe, I; Jones, B; Lindborg, SR; Meehan, K; Morris, PL; Pickard, A; Roth, J; Taylor, CC; Wright, P, 2003)
"The association of clinical characteristics with a sustained response was investigated in 37 partially treatment-refractory outpatients with a DSM-III-R diagnosis of chronic schizophrenia who had been assigned to clozapine treatment in a double-blind, haloperidol-controlled, long-term (29-week) study of clozapine."	9.10	Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. ( Kane, JM; Marder, SR; McMeniman, M; Schooler, NR; Umbricht, DS; Wirshing, DA; Wirshing, WC, 2002)
"The aim of this study was to investigate the effect of reduced haloperidol, the main metabolite of the antipsychotic drug haloperidol, on psychopathology improvement and extrapyramidal adverse effects in acute schizophrenia."	9.09	Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia. ( Braun, V; Meyer, FP; Neuhof, S; Ulrich, S, 1999)
"The purpose of this study was to evaluate the clinical safety and efficacy of risperidone compared to haloperidol in patients with treatment-refractory schizophrenia."	9.09	Risperidone in treatment-refractory schizophrenia. ( Green, MF; Marder, SR; Marshall, BD; Mintz, J; Wirshing, DA; Wirshing, WC, 1999)
"Clomipramine, haloperidol, and placebo were compared with baseline in the treatment of autism, and overall outcome, specific symptoms, and side effects were examined."	9.09	Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. ( Gow, R; Konstantareas, M; Parker, K; Remington, G; Sloman, L, 2001)
"The purpose of this study was to examine the efficacy and side effects of haloperidol, chlorpromazine, and lorazepam for the treatment of the symptoms of delirium in adult AIDS patients in a randomized, double-blind, comparison trial."	9.08	A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. ( Breitbart, W; Corbera, K; Derevenco, M; Grau, C; Jacobson, P; Lund, S; Marotta, R; Platt, MM; Raymond, S; Weisman, H, 1996)
"This multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of three doses of sertindole (12, 20, and 24 mg/day) and haloperidol (4, 8, and 16 mg/day) in the treatment of psychotic symptoms for 497 hospitalized patients with schizophrenia."	9.08	Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. ( Daniel, DG; Kane, JM; Kashkin, KB; Mack, RJ; Sebree, TB; Tamminga, CA; Wallin, BA; Wozniak, PJ; Zimbroff, DL, 1997)
"In two double-blind trials conducted in North America, 513 patients with chronic schizophrenia received risperidone, haloperidol, or placebo."	9.08	The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. ( Chouinard, G; Davis, JM; Marder, SR, 1997)
" Patients with chronic schizophrenia were treated with risperidone at 1 mg/day (n = 25), 4 mg/day (n = 27), 8 mg/day (n = 29), 12 mg/day (n = 31), or 16 mg/day (n = 29), or 10 mg/day of haloperidol for 8 weeks."	9.08	Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. ( Bäuml, J; Ferrero, F; Fuger, J; Geretsegger, C; Kasper, S; Kissling, W; Möller, HJ; Schubert, H, 1997)
"The purpose of this study was to compare the efficacy of olanzapine with that of chlorpromazine plus benztropine in patients with treatment-resistant schizophrenia."	9.08	Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. ( Bartko, JJ; Conley, RR; Gounaris, C; Hegerty, J; Lingle, J; Love, R; Peszke, M; Richardson, C; Tamminga, CA; Zaremba, S, 1998)
"After individual determination of neuroleptic threshold (NT) doses of haloperidol, 106 patients with schizophrenia or schizoaffective disorder (Research Diagnostic Criteria) were treated openly at such doses (mean, 3."	9.07	Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. ( Hogarty, GE; McEvoy, JP; Steingard, S, 1991)
"Zetidoline (ZTD), a compound chemically unrelated to any available antipsychotic, with selective dopamine receptor-blocking properties, was compared with haloperidol (HLP) in a double-blind study on 56 in-patients who had either first episodes or acute relapses of schizophrenia."	9.05	Zetidoline, a new antipsychotic. First controlled trial in acute schizophrenia. ( Dubini, A; Freeman, HL; Levine, S; Silverstone, T, 1984)
"Pooled data from two 52-week, randomized, double-blind, multicenter, comparative trials of aripiprazole and haloperidol in acutely ill patients with schizophrenia were analyzed."	8.84	Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. ( Carson, WH; Crandall, DT; Eudicone, J; Kane, JM; Marcus, RN; Pikalov, A; Swyzen, W, 2007)
"Consistent with prior research, haloperidol-treated patients with bipolar disorder appeared to be more vulnerable to the development of EPS than those with schizophrenia."	8.83	Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. ( Berg, PH; Briggs, SD; Cavazzoni, PA; Kane, JM; Kryzhanovskaya, LA; Roddy, TE; Tohen, M, 2006)
"The frequency and severity of extrapyramidal syndrome (EPS) were evaluated in patients with DSM-III or DSM-IV schizophrenia in the acute phase (- 8 weeks) of randomized, double-blind, controlled trials from the integrated olanzapine clinical trial database."	8.82	An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. ( Beasley, CM; Berg, PH; Carlson, CD; Cavazzoni, PA; Kane, JM; Wei, H, 2003)
"We studied the relationship between the efficiency of muscarinic receptor antagonists in preventing haloperidol-induced catatonia and their activity in tests for the interaction of ligands with various subtypes of muscarinic receptors (M1-M4) in rats."	7.72	Effect of M4-cholinoceptor blockade on haloperidol-produced catatonic syndrome in rats. ( Beliaev, VA; Dagaev, SG; Dolgo-Saburov, VB; Filko, OA; Khrabrova, AV; Kosmachev, AB; Kubarskaya, LG; Libman, NM; Podosinovikova, NP; Sanotskii, VI, 2004)
"An unusual, acute extrapyramidal reaction, which resulted from treatment with haloperidol and which was unresponsive to standard anticholinergic treatment and indistinguishable on clinical grounds from acute catatonia, is described."	7.65	Catatonia and malignant syndrome: a possible complication of neuroleptic administration. Report of a case involving haloperidol. ( Kelly, MJ; Weinberger, DR, 1977)
"Comorbid cocaine abuse adversely affects clinical outcomes in schizophrenia."	6.71	Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. ( Campbell, EC; Caroff, SN; Cornish, J; Kondrich, J; Mann, SC; O'Brien, C; Sayers, SL, 2005)
"Olanzapine has been reported as less likely to cause EPS and may improve some negative signs."	6.69	The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine. ( Allan, ER; Alpert, M; Connolly, B; Crichton, J; Sison, CE, 1998)
" Using an optimizing dosage regime, the outcome variables studied were aggression frequency and the number and nature of emergent side effects."	6.67	Aggression in the demented patient: a double-blind study of loxapine versus haloperidol. ( Ancill, RJ; Carlyle, W; Sheldon, L, 1993)
" Dosage of these two drugs were 450 = 133 mg and 32 +/- 9."	6.67	[A double-blind study of metoclopramide in the treatment of schizophrenia and determination of prolactin]. ( Gu, SF, 1992)
" The total incidence of serious adverse events in the short-term double-blind programme was approximately 2% for both remoxipride and haloperidol."	6.67	Safety evaluation in both short- and long-term treatment of schizophrenia with remoxipride. ( Englund, A; Lawrie, V; Lewander, T; Morrison, D; Schlachet, A; Westerbergh, SE, 1990)
"Haloperidol dose was positively correlated with plasma protein carbonyls."	5.39	Oxidative stress in schizophrenia patients treated with long-acting haloperidol decanoate. ( Bošković, M; Grabnar, I; Kores Plesničar, B; Terzič, T; Vovk, T, 2013)
"Further, neither catalepsy intensity nor its latency was affected by a combination of the selective A(1)R antagonist DPCPX (1 mg/kg), with the larger doses of both anticholinergics."	5.36	Synergism of theophylline and anticholinergics to inhibit haloperidol-induced catalepsy: a potential treatment for extrapyramidal syndromes. ( Arankowsky-Sandoval, G; Ceballos-Huerta, F; Góngora-Alfaro, JL; González-Lugo, OE; Jiménez-Capdeville, ME, 2010)
"Haloperidol patients were more often single and institutionalised, less educated, had more residual schizophrenia, were longer hospitalised in the previous year, took more corrective and psychotropic drugs and had more extrapyramidal symptoms (EPS) and gynaecomastia (all significantly)."	5.35	Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. ( Albert, A; De Graeve, D; Gillain, B; Peuskens, J; Van Vleymen, B, 2009)
"Haloperidol was prescribed to control psychotic symptoms."	5.32	Potentiation of haloperidol neurotoxicity in acute hyperthyroidism: report of a case. ( Chu, H; Hsu, YD; Lin, JC, 2004)
"Catalepsy was measured in rats using both the cross-legged position test and the bar test."	5.31	Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy. ( Colpaert, FC; Kleven, MS; Koek, W; Prinssen, EP, 2000)
"Risperidone-treated patients had a significantly higher DAI-10 score compared to haloperidol-treated patients."	5.31	Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). ( Edgell, E; García-Cabeza, I; Gómez, JC; González de Chavez, M; Sacristán, JA, 2001)
"Malignant syndrome is a disease characterized by high fever, extrapyramidal syndrome and dysautonomia recognized during or at the time of stopping administration of antipsychotic medication and it is the most severe and lethal side effect of antipsychotic medication."	5.30	[A case of malignant syndrome triggered by the use of haloperidol and chrorpromazine]. ( Fujimoto, K; Konishi, K; Kubota, M; Ogawa, H, 1997)
"Glycine was administered in an effort to facilitate endogenous glutamatergic transmission at the level of the N-methyl-D-aspartate (NMDA) receptor complex, since a glutamatergic deficiency in the pathophysiology of schizophrenia has been postulated."	5.28	Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. ( Banay-Schwartz, M; Cohen, CG; Deutsch, SI; Leighton, M; Rosse, RB; Scarcella, E; Theut, SK, 1989)
"Two typical recurrent episodes of neuroleptic malignant syndrome (NMS) in the same patient are described."	5.27	Recurrent neuroleptic malignant syndrome due to tiapride and haloperidol: the possible role of D-2 dopamine receptors. ( Hermesh, H; Huberman, M; Kott, E; Radvan, H, 1984)
"A case of neuroleptic malignant syndrome (NMS) with an abrupt onset was terminated quickly with i."	5.27	Resolution of neuroleptic malignant syndrome with dantrolene sodium: case report. ( Jaffe, JH; Khan, A; Morrison, B; Nelson, WH, 1985)
"Chronic schizophrenic patients were maintained for six months on a dosage of haloperidol adjusted to give optimum clinical effect."	5.26	Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia. ( Bishop, M; Coppen, A; Rao, VA, 1980)
"The HARPOON study will provide relevant information on the efficacy and safety of prophylactic haloperidol treatment for in-hospital delirium and its effects on relevant clinical outcomes in elderly at-risk medical and surgical patients."	5.19	Efficacy and safety of haloperidol prophylaxis for delirium prevention in older medical and surgical at-risk patients acutely admitted to hospital through the emergency department: study protocol of a multicenter, randomised, double-blind, placebo-control ( Anten, S; Bet, PM; Boelaarts, L; de Graaf, K; de Vries, OJ; Diepeveen, SH; Kamper, AM; Kramer, MH; Kuipéri, E; Lagaay, AM; Nanayakkara, PW; Pons, D; Schrijver, EJ; Siegel, A; van de Ven, PM; van Marum, RJ; van Strien, AM; Verburg, A, 2014)
"In patients with early-episode schizophrenia, aripiprazole demonstrates greater improvement than haloperidol on PANSS items related to social functioning."	5.14	Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia. ( Baker, RA; Docherty, JP; Eudicone, J; Mankoski, R; Marcus, RN; Mathew, S; McQuade, RD, 2010)
" Fifty-one patients diagnosed with paranoid schizophrenia received haloperidol in combination with nifedipine (25 patients) or haloperidol only (26 patients) during 26 weeks."	5.13	[The use of nifedipine as a corrector of extrapyramidal side-effects of classical neuroleptics]. ( Popov, MIu, 2008)
"This double-blind, placebo-controlled study investigated the efficacy and safety of intramuscular (IM) aripiprazole and IM haloperidol for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder."	5.12	Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. ( Andrezina, R; Carson, WH; Iwamoto, T; Josiassen, RC; Manos, G; Marcus, RN; Oren, DA; Stock, E, 2006)
"To compare the safety and estimate the response profile of olanzapine, a second-generation antipsychotic, to haloperidol in the treatment of delirium in the critical care setting."	5.11	Olanzapine vs haloperidol: treating delirium in a critical care setting. ( Bergeron, N; Dumont, M; Gottfried, SB; Skrobik, YK, 2004)
"The ABC-C and the Childhood Autism Rating Scale scores improved with cyproheptadine."	5.11	Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. ( Akhondzadeh, S; Amini, H; Erfani, S; Gudarzi, SS; Mohammadi, MR; Tehrani-Doost, M; Yasamy, MT, 2004)
"Patients with a first episode of schizophrenia, schizoaffective disorder, or schizophreniform disorder (N=167) were randomly assigned to double-blind treatment with olanzapine (mean modal dose= 9."	5.11	Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. ( Christensen, BK; Gur, RC; Hamer, RM; Keefe, RS; Lewine, RR; Lieberman, JA; Sanger, TM; Seidman, LJ; Sharma, T; Sitskoorn, MM; Tohen, M; Tollefson, GD; Yurgelun-Todd, DA, 2004)
"Sixty-three outpatients with schizophrenia who met retrospective and prospective criteria for either residual positive or residual negative symptoms entered a 16-week double-blind, parallel-groups comparison of olanzapine and haloperidol."	5.11	Olanzapine treatment of residual positive and negative symptoms. ( Ball, MP; Buchanan, RW; Carpenter, WT; Gold, JM; Kirkpatrick, B; McMahon, RP; Weiner, E, 2005)
"Patients with DSM-IV-diagnosed schizophrenia or schizoaffective disorder requiring long-term antipsychotic treatment were randomly assigned to open-label oral quetiapine or intramuscular haloperidol decanoate for 48 weeks."	5.11	Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. ( Glick, ID; Marder, SR, 2005)
"This study investigated safety and effectiveness of olanzapine in monotherapy compared with conventional antipsychotics in treatment of acute inpatients with schizophrenia."	5.11	Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study. ( Alvarez, E; Bobes, J; Cañas, F; Carrasco, JL; Ciudad, A; Gascón, J; Gibert, J; Gómez, JC; Gutiérrez, M, 2005)
"Aripiprazole is an investigational agent for treating schizophrenia that has a novel pharmacologic profile."	5.10	Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. ( Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL, 2002)
"The superiority of olanzapine to haloperidol with respect to a decreased incidence of treatment-emergent extrapyramidal syndromes (EPS) in patients with schizophrenia was demonstrated in studies conducted in both Japan and Western countries."	5.10	Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. ( Beasley, CM; Inada, T; Tanaka, Y; Walker, DJ, 2003)
"Subjects (N=24) who met DSM-IV criteria for schizophrenia were randomly assigned to 6 weeks of double-blind treatment with either olanzapine, 7."	5.10	Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. ( Booij, J; de Haan, L; Dingemans, PM; Lavalaye, J; Linszen, D; van Bruggen, M, 2003)
" haloperidol during the first 24 hours of treatment of acute schizophrenia."	5.10	Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. ( Alaka, K; Battaglia, J; Birkett, M; Bitter, I; Breier, A; Chouinard, G; Ferchland-Howe, I; Jones, B; Lindborg, SR; Meehan, K; Morris, PL; Pickard, A; Roth, J; Taylor, CC; Wright, P, 2003)
"The association of clinical characteristics with a sustained response was investigated in 37 partially treatment-refractory outpatients with a DSM-III-R diagnosis of chronic schizophrenia who had been assigned to clozapine treatment in a double-blind, haloperidol-controlled, long-term (29-week) study of clozapine."	5.10	Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. ( Kane, JM; Marder, SR; McMeniman, M; Schooler, NR; Umbricht, DS; Wirshing, DA; Wirshing, WC, 2002)
"This 3-week randomized, double-blind, placebo-controlled study included 156 bipolar disorder patients with a current manic or mixed episode who received a mood stabilizer (lithium or divalproex) and placebo, risperidone, or haloperidol."	5.10	Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. ( Bowden, CL; Ghaemi, SN; Grossman, F; Okamoto, A; Sachs, GS, 2002)
"The aim of this study was to investigate the effect of reduced haloperidol, the main metabolite of the antipsychotic drug haloperidol, on psychopathology improvement and extrapyramidal adverse effects in acute schizophrenia."	5.09	Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia. ( Braun, V; Meyer, FP; Neuhof, S; Ulrich, S, 1999)
"The purpose of this study was to evaluate the clinical safety and efficacy of risperidone compared to haloperidol in patients with treatment-refractory schizophrenia."	5.09	Risperidone in treatment-refractory schizophrenia. ( Green, MF; Marder, SR; Marshall, BD; Mintz, J; Wirshing, DA; Wirshing, WC, 1999)
"Effects of flexible doses of risperidone and haloperidol were compared in 77 psychotic patients (83% with chronic schizophrenia) with disturbing neuroleptic-induced EPS (risperidone 40 patients, haloperidol 37)."	5.09	Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. ( de Groot, IW; Haffmans, PM; Heck, AH; Hoencamp, E, 2000)
"Clomipramine, haloperidol, and placebo were compared with baseline in the treatment of autism, and overall outcome, specific symptoms, and side effects were examined."	5.09	Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. ( Gow, R; Konstantareas, M; Parker, K; Remington, G; Sloman, L, 2001)
"The hypothesis that differences in drug effects of risperidone and haloperidol on negative symptoms in schizophrenia are secondary to effects on positive, extrapyramidal, and depressive symptoms was investigated by means of an analysis of the data from the USA-Canada risperidone double-blind randomized clinical trial of 523 chronic schizophrenic patients."	5.08	A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. ( Borison, RL; Chouinard, G; Möller, HJ; Müller, H; Schooler, NR, 1995)
"The purpose of this study was to examine the efficacy and side effects of haloperidol, chlorpromazine, and lorazepam for the treatment of the symptoms of delirium in adult AIDS patients in a randomized, double-blind, comparison trial."	5.08	A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. ( Breitbart, W; Corbera, K; Derevenco, M; Grau, C; Jacobson, P; Lund, S; Marotta, R; Platt, MM; Raymond, S; Weisman, H, 1996)
"After a < or = 1-day screening period, 36 consecutive hospitalized patients with bipolar disorder, manic or mixed phase and with psychotic features, were randomly assigned to receive either divalproex 20 mg/kg/day or haloperidol 0."	5.08	A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. ( Bennett, JA; Keck, PE; McElroy, SL; Stanton, SP; Strakowski, SM; Tugrul, KC, 1996)
"This multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of three doses of sertindole (12, 20, and 24 mg/day) and haloperidol (4, 8, and 16 mg/day) in the treatment of psychotic symptoms for 497 hospitalized patients with schizophrenia."	5.08	Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. ( Daniel, DG; Kane, JM; Kashkin, KB; Mack, RJ; Sebree, TB; Tamminga, CA; Wallin, BA; Wozniak, PJ; Zimbroff, DL, 1997)
"In two double-blind trials conducted in North America, 513 patients with chronic schizophrenia received risperidone, haloperidol, or placebo."	5.08	The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. ( Chouinard, G; Davis, JM; Marder, SR, 1997)
" Patients with chronic schizophrenia were treated with risperidone at 1 mg/day (n = 25), 4 mg/day (n = 27), 8 mg/day (n = 29), 12 mg/day (n = 31), or 16 mg/day (n = 29), or 10 mg/day of haloperidol for 8 weeks."	5.08	Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. ( Bäuml, J; Ferrero, F; Fuger, J; Geretsegger, C; Kasper, S; Kissling, W; Möller, HJ; Schubert, H, 1997)
"The purpose of this study was to compare the efficacy of olanzapine with that of chlorpromazine plus benztropine in patients with treatment-resistant schizophrenia."	5.08	Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. ( Bartko, JJ; Conley, RR; Gounaris, C; Hegerty, J; Lingle, J; Love, R; Peszke, M; Richardson, C; Tamminga, CA; Zaremba, S, 1998)
"For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation."	5.08	A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. ( Bell, K; Cooper, TB; Devanand, DP; Marder, K; Mayeux, R; Michaels, KS; Pelton, GH; Sackeim, HA; Sullivan, MA, 1998)
"After individual determination of neuroleptic threshold (NT) doses of haloperidol, 106 patients with schizophrenia or schizoaffective disorder (Research Diagnostic Criteria) were treated openly at such doses (mean, 3."	5.07	Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. ( Hogarty, GE; McEvoy, JP; Steingard, S, 1991)
"The antipsychotic effect of remoxipride was compared to that of haloperidol in a randomized double-blind study with parallel group design comprising 98 patients with schizophrenia or schizophreniform disorder according to DSM-III."	5.06	A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders. ( Cosyns, P; de Bleeker, E; Deleu, G; Lotstra, F; Masson, A; Mendlewicz, J; Mertens, C; Parent, M; Peuskens, J; Suy, E, 1990)
"Zetidoline (ZTD), a compound chemically unrelated to any available antipsychotic, with selective dopamine receptor-blocking properties, was compared with haloperidol (HLP) in a double-blind study on 56 in-patients who had either first episodes or acute relapses of schizophrenia."	5.05	Zetidoline, a new antipsychotic. First controlled trial in acute schizophrenia. ( Dubini, A; Freeman, HL; Levine, S; Silverstone, T, 1984)
" When the risk of adverse effects is analyzed, olanzapine and clozapine are afflicted with the highest risk of inducing weight gain and haloperidol with extrapyramidal symptoms."	4.87	A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo. ( Aursnes, I; Gaasemyr, J; Klemp, M; Natvig, B; Skomedal, T; Tvete, IF, 2011)
" This report describes a case of drug-induced dysphagia in a 53-year-old man receiving haloperidol for treatment of schizophrenia."	4.84	Neuroleptic-induced dysphagia: case report and literature review. ( Dziewas, R; Nabavi, DG; Reker, T; Ringelstein, EB; Ritter, M; Schilling, M; Schnabel, M; Warnecke, T, 2007)
"Pooled data from two 52-week, randomized, double-blind, multicenter, comparative trials of aripiprazole and haloperidol in acutely ill patients with schizophrenia were analyzed."	4.84	Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. ( Carson, WH; Crandall, DT; Eudicone, J; Kane, JM; Marcus, RN; Pikalov, A; Swyzen, W, 2007)
"Consistent with prior research, haloperidol-treated patients with bipolar disorder appeared to be more vulnerable to the development of EPS than those with schizophrenia."	4.83	Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. ( Berg, PH; Briggs, SD; Cavazzoni, PA; Kane, JM; Kryzhanovskaya, LA; Roddy, TE; Tohen, M, 2006)
"The frequency and severity of extrapyramidal syndrome (EPS) were evaluated in patients with DSM-III or DSM-IV schizophrenia in the acute phase (- 8 weeks) of randomized, double-blind, controlled trials from the integrated olanzapine clinical trial database."	4.82	An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. ( Beasley, CM; Berg, PH; Carlson, CD; Cavazzoni, PA; Kane, JM; Wei, H, 2003)
"The objective of this meta-analysis is to summarize the efficacy and tolerability of the new antipsychotics risperidone, olanzapine, sertindole and quetiapine in schizophrenia compared to placebo and conventional antipsychotics."	4.80	Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. ( Abraham, D; Kissling, W; Leucht, S; Pitschel-Walz, G, 1999)
" Efficacy in treating overall psychopathology in acute schizophrenia as measured by the BPRS0-6 total score was demonstrated at 10 mg/day versus placebo; at doses in a 5-20 mg/day range, olanzapine was comparable or superior to haloperidol."	4.79	Dosing the antipsychotic medication olanzapine. ( Nemeroff, CB, 1997)
"3-3 mg/kg) did not induce EPS signs by itself; however, it significantly potentiated bradykinesia induction with a low dose of haloperidol (0."	3.81	Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice. ( Fujiwara, M; Mizuguchi, Y; Morimoto, T; Ohno, Y; Shimizu, S; Sobue, A, 2015)
"A 60-year-old man with rapidly progressive frontotemporal dementia complicated by severe aggression was managed in specialised psychogeriatric services and high-dose haloperidol was used."	3.80	Managing severe aggression in frontotemporal dementia. ( Flynn, P; McKellar, D; Powell, A; Rischbieth, S, 2014)
"To compare the effectiveness of intramuscular (IM) olanzapine and typical IM antipsychotics in naturalistically treated acutely agitated patients with schizophrenia or acute mania."	3.75	Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation. ( Castle, DJ; Isik, T; Karagianis, J; Kim, CY; Melamed, Y; Omar, AN; Pidrman, V; Rosales, JI; Sarosi, A; Treuer, T; Udristoiu, T, 2009)
" The initial doses varied widely, ranging from 1 to 30 mg, with a maximum total daily dosage of 100 mg."	3.74	Overview: efficacy and safety of the rapid neuroleptization method with injectable haloperidol. ( Donlon, PT; Hopkin, J; Tupin, JP, 1979)
"We studied the relationship between the efficiency of muscarinic receptor antagonists in preventing haloperidol-induced catatonia and their activity in tests for the interaction of ligands with various subtypes of muscarinic receptors (M1-M4) in rats."	3.72	Effect of M4-cholinoceptor blockade on haloperidol-produced catatonic syndrome in rats. ( Beliaev, VA; Dagaev, SG; Dolgo-Saburov, VB; Filko, OA; Khrabrova, AV; Kosmachev, AB; Kubarskaya, LG; Libman, NM; Podosinovikova, NP; Sanotskii, VI, 2004)
"The authors added haloperidol, a potent D(2) blocker, to ongoing treatment with clozapine in patients with schizophrenia to determine the effects of this combination on dopamine D(2) receptor blockade, prolactin level, and extrapyramidal side effects."	3.71	Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. ( Daskalakis, J; Kapur, S; Remington, G; Roy, P; Zipursky, R, 2001)
"In 20 patients with schizophrenia [Diagnostic and Statistical Manual of Mental Disorders (Third Edition-Revised)] treated with mean daily doses of risperidone ranging from 0."	3.70	Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients. ( Dähne, I; Dresel, S; Hahn, K; Mager, T; Scherer, J; Tatsch, K, 1998)
"The objectives of this study were to determine the doses of olanzapine (OLZ), risperidone (RIS), and haloperidol (HAL) used in clinical practice in outpatients with schizophrenia and the rates of occurrence of extrapyramidal symptoms (EPS) and other adverse events, clinical response, and use of concomitant medications."	3.70	Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina. ( Gómez, JC; Gregor, KJ; Montejo, AL; Sacristán, JA; Vieta, E, 2000)
"The enhancement of immobility in a forced swimming test of mice induced by repeated treatment with phencyclidine and amphetamine swimming "normalization" test of mice were used as animal models of negative and positive symptoms of schizophrenia, respectively."	3.70	Atypical antipsychotic effects of quetiapine fumarate in animal models. ( Dai, J; Guan, HJ; Zhu, XZ, 2000)
"We present extrapyramidal syndrome in 22 children (5 en 1984 and 17 during 1985) who received clebopride (15), metoclopramide (6) and haloperidol (1), almost all at the level of therapeutic doses, which fact seems to indicated a idiosyncratic factor."	3.67	[Drug-induced extrapyramidal syndrome. Apropos of 22 cases]. ( Calvo Fernández, J; Castro-Gago, M; Couce Pico, M; López Rois, F; Novo, I, 1987)
"We present the case of a 35-year-old man who developed symptoms of the neuroleptic malignant syndrome (NMS) after taking prescribed, moderately high, therapeutic doses of haloperidol."	3.67	Neuroleptic malignant syndrome. ( Lucid, EJ; Martin, ML; Walker, RW, 1985)
" Muscle rigidity was not affected by etybenzatropine or diazepam, but dantrolene, a direct-acting skeletal muscle relaxant, provided muscle relaxation with a concomitant decrease of fever and serum creatine kinase."	3.66	Beneficial effects of dantrolene in the treatment of neuroleptic malignant syndrome: a report of two cases. ( Bismuth, C; Conso, F; de Rohan-Chabot, P; Elkharrat, D; Gajdos, P; Goulon, M, 1983)
"An unusual, acute extrapyramidal reaction, which resulted from treatment with haloperidol and which was unresponsive to standard anticholinergic treatment and indistinguishable on clinical grounds from acute catatonia, is described."	3.65	Catatonia and malignant syndrome: a possible complication of neuroleptic administration. Report of a case involving haloperidol. ( Kelly, MJ; Weinberger, DR, 1977)
" For 80 patients treated with sodium valproate, the mean ± SD dosage was 1541."	2.80	Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, double-blind, parallel-group trial. ( Asadollahi, S; Azadbakht, A; Hatamabadi, H; Heidari, K; Mirmohseni, L; Vafaee, R; Yunesian, S, 2015)
"The authors conducted a multicenter, double-blind, placebo-controlled, randomized trial of flexibly dosed quetiapine and haloperidol."	2.72	Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. ( Copenhaver, M; Katz, IR; Mintzer, JE; Schneider, L; Street, J; Tariot, PN; Williams-Hughes, C, 2006)
"We have presented pharmacokinetic parameters of bromperidol (BP) in 14 healthy Korean subjects."	2.72	Pharmacokinetic parameters of bromperidol in Korean subjects. ( Kim, HG; Kim, JW; Kim, YG; Lee, SY, 2006)
"Olanzapine-treated patients experienced a lower rate of treatment-emergent parkinsonism and akathisia but had significantly more weight gain, compared with the haloperidol-treated patients."	2.71	Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. ( Green, AI; Gur, RE; Hamer, RM; Kahn, R; Lieberman, JA; McEvoy, J; Perkins, D; Sharma, T; Tohen, M; Tollefson, G; Wei, H; Zipursky, R, 2003)
"Comorbid cocaine abuse adversely affects clinical outcomes in schizophrenia."	2.71	Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. ( Campbell, EC; Caroff, SN; Cornish, J; Kondrich, J; Mann, SC; O'Brien, C; Sayers, SL, 2005)
"Olanzapine has been reported as less likely to cause EPS and may improve some negative signs."	2.69	The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine. ( Allan, ER; Alpert, M; Connolly, B; Crichton, J; Sison, CE, 1998)
"Haloperidol treatment has been shown to produce oxidative stress in patients with acute psychosis."	2.69	Haloperidol-induced extrapyramidal reaction: lack of protective effect by vitamin E. ( Eranti, VS; Gangadhar, BN; Janakiramaiah, N, 1998)
"Haloperidol-treated first-episode patients experienced statistically significantly more extrapyramidal symptoms than haloperidol-treated multiple-episode patients."	2.69	Olanzapine versus haloperidol treatment in first-episode psychosis. ( Beasley, C; Grundy, S; Lieberman, JA; Sanger, TM; Tohen, M; Tollefson, GD, 1999)
" They underwent a series of psychomotor and cognitive tests 1 hour before and 3 and 6 hours after dosing on days 1 and 5."	2.69	Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. ( de Bie, A; Louwerens, JW; Milius, H; Muntjewerff, ND; O'Hanlon, JF; Patat, A; Ramaekers, JG; Rosenzweig, P, 1999)
"Haloperidol dose was negatively associated with improvement in positive symptoms (r = -."	2.68	Symptom change and extrapyramidal side effects during acute haloperidol treatment in chronic geriatric schizophrenics. ( Pardo, M; Pollack, S; Weisbard, JJ, 1997)
"Haloperidol-associated treatment-limiting adverse events were experienced by 41% of the patients."	2.68	Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. ( Jackson, C; Nesbitt, L; Sallee, FR; Sethuraman, G; Sine, L, 1997)
" Using an optimizing dosage regime, the outcome variables studied were aggression frequency and the number and nature of emergent side effects."	2.67	Aggression in the demented patient: a double-blind study of loxapine versus haloperidol. ( Ancill, RJ; Carlyle, W; Sheldon, L, 1993)
" Dosage of these two drugs were 450 = 133 mg and 32 +/- 9."	2.67	[A double-blind study of metoclopramide in the treatment of schizophrenia and determination of prolactin]. ( Gu, SF, 1992)
" The total incidence of serious adverse events in the short-term double-blind programme was approximately 2% for both remoxipride and haloperidol."	2.67	Safety evaluation in both short- and long-term treatment of schizophrenia with remoxipride. ( Englund, A; Lawrie, V; Lewander, T; Morrison, D; Schlachet, A; Westerbergh, SE, 1990)
"Fluperlapine (NB-106-689) was tested on 26 schizophrenic patients in an open and crossover study."	2.66	Differential effects of a new dibenzo-epine neuroleptic compared with haloperidol. Results of an open and crossover study. ( Bartels, M; Gärtner, HJ; Heimann, H; Mann, K; Schied, HW; Wagner, W, 1987)
" Overall, 25 years of experience have indicated that haloperidol can be used safely and effectively to manage a variety of psychiatric illnesses, so long as dosage and method of administration are adjusted to individual patients' needs."	2.65	Haloperidol: a quarter century of experience. ( Ayd, FJ; Settle, EC, 1983)
" In the 1-day dosage group the amount of anticholinergics were significantly reduced (2."	2.64	[Extrapyamidal side-effects with 1-day dosage of haloperidol (author's transl)]. ( Matzner, G; Rüther, E; Uriarte, V, 1978)
"Based on findings from 34 blinded, randomized controlled trials, common acute adverse effects of second-generation antipsychotics and haloperidol were headache, dizziness, insomnia, and somnolence."	2.58	Evidence-Based Review Of Pharmacotherapy For Acute Agitation. Part 2: Safety. ( Zun, LS, 2018)
"Notably, catalepsy induced by haloperidol, a D2 antagonist, is augmented, whereas catalepsy induced by SCH23390, a D1 antagonist, was not affected in H-FABP null mice."	2.47	[Regulation of dopaminergic neuronal activity by heart-type fatty acid binding protein in the brain]. ( Fukunaga, K; Owada, Y; Shioda, N; Yamamoto, Y, 2011)
"Most traditional neuroleptics have a narrow therapeutic-to-toxic index, and thus, the novel antipsychotics are the result of a search to substantially widen the distance between the dose that treats psychosis and the one that produces adverse effects."	2.40	The relationship of pharmacology to side effects. ( Casey, DE, 1997)
" Three notions have been utilized conceptually to explain the distinction between atypical versus typical antipsychotic drugs: 1) dose-response separation between particular pharmacologic functions; 2) anatomic specificity of particular pharmacologic activities; 3) neurotransmitter receptor interactions and pharmacodynamics."	2.39	Mechanisms of action of atypical antipsychotic drugs: a critical analysis. ( Kinon, BJ; Lieberman, JA, 1996)
" It is suggested that additional studies, carefully designed, on dosage and plasma levels could help in achieving the lowest possible therapeutic dosage and thus in minimizing side effects."	2.37	Blood levels of neuroleptics: state of the art. ( Simpson, GM; Yadalam, K, 1985)
"HP produced a full blown catalepsy, akinesia and a significant impairment in locomotion and antioxidant status."	1.48	Interplay between adenosine receptor antagonist and cyclooxygenase inhibitor in haloperidol-induced extrapyramidal effects in mice. ( Anoopkumar-Dukie, S; Arora, D; Grant, GD; Hall, S; Kinra, M; Mallik, SB; Mudgal, J; Nampoothiri, M; Rao, CM, 2018)
"Haloperidol is an effective antipsychotic drug for treatment of schizophrenia, but prolonged use can lead to debilitating side effects."	1.42	Neurochemical Metabolomics Reveals Disruption to Sphingolipid Metabolism Following Chronic Haloperidol Administration. ( Batman, AM; Beardsley, PM; Crowley, JJ; McClay, JL; van den Oord, EJ; Vann, RE; Vunck, SA, 2015)
"Blonanserin is a new atypical antipsychotic drug that shows high affinities to dopamine D2 and 5-HT2 receptors; however, the mechanisms underlying its atypicality are not fully understood."	1.42	Atypical antipsychotic properties of AD-6048, a primary metabolite of blonanserin. ( Masui, A; Minamimoto, S; Mizobe, Y; Mizuguchi, Y; Ochiai, M; Ohno, Y; Shimizu, S; Tamura, M; Tatara, A, 2015)
"Extrapyramidal symptoms (EPSs) are common adverse effects of antipsychotics."	1.39	The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol. ( Bozina, N; Mihaljević-Peles, A; Muck-Seler, D; Nikolac-Perkovic, M; Sagud, M; Vuksan-Cusa, B; Zivković, M, 2013)
"Haloperidol dose was positively correlated with plasma protein carbonyls."	1.39	Oxidative stress in schizophrenia patients treated with long-acting haloperidol decanoate. ( Bošković, M; Grabnar, I; Kores Plesničar, B; Terzič, T; Vovk, T, 2013)
"Haloperidol and vehicle treated male mice heterozygous (HET) or homozygous (HOM) for the mutation, or wild type (WT), were evaluated for open field locomotion, catalepsy duration, pole test performance and rota-rod latency to fall."	1.38	Alteration in RGS2 expression level is associated with changes in haloperidol induced extrapyramidal features in a mutant mouse model. ( Broner, EC; Greenbaum, L; Kohn, Y; Lerer, B; Lifschytz, T; Slonimsky, A; Zozulinsky, P, 2012)
"Here we used the animal models of extrapyramidal disorders cited above, which were performed in two distinct experiments: orofacial dyskinesia (OD)/catalepsy induced by acute reserpine and subchronic haloperidol after (experiment 1) and before (experiment 2) oral treatment with pecan shell aqueous extract (AE), a natural and promissory antioxidant."	1.37	Comparative study between two animal models of extrapyramidal movement disorders: prevention and reversion by pecan nut shell aqueous extract. ( Barcelos, RC; Benvegnú, DM; Boufleur, N; Bürger, ME; Dias, VT; Dolci, GS; Pase, CS; Reckziegel, P; Segat, HJ; Trevizol, F, 2011)
"Further, neither catalepsy intensity nor its latency was affected by a combination of the selective A(1)R antagonist DPCPX (1 mg/kg), with the larger doses of both anticholinergics."	1.36	Synergism of theophylline and anticholinergics to inhibit haloperidol-induced catalepsy: a potential treatment for extrapyramidal syndromes. ( Arankowsky-Sandoval, G; Ceballos-Huerta, F; Góngora-Alfaro, JL; González-Lugo, OE; Jiménez-Capdeville, ME, 2010)
"7 mg/kg IM once), and for 3 days before hospitalization with clomipramine HCl at a prescribed dosage of 3."	1.35	Extrapyramidal side effects in a blue and gold macaw (Ara ararauna) treated with haloperidol and clomipramine. ( Albright, JD; Hickam, HD; Lynch, MJ; Morrisey, JK; Starkey, SR, 2008)
"Haloperidol patients were more often single and institutionalised, less educated, had more residual schizophrenia, were longer hospitalised in the previous year, took more corrective and psychotropic drugs and had more extrapyramidal symptoms (EPS) and gynaecomastia (all significantly)."	1.35	Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. ( Albert, A; De Graeve, D; Gillain, B; Peuskens, J; Van Vleymen, B, 2009)
"Aripiprazole has been used effectively to treat schizophrenia in the clinic; however, its mechanisms of action are not clear."	1.35	Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. ( Deng, C; Han, M; Huang, XF, 2009)
"Aripiprazole was administered at fixed doses of 15 mg/day, 20 mg/day, or 30 mg/day."	1.35	The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. ( Assunção-Talbott, S; Eudicone, JM; Glick, ID; Mankoski, R; Marcus, RN; Tran, QV, 2009)
"Because catalepsy is thought to be a good predictor of extrapyramidal symptoms in humans, treatment with orexin-1 antagonists might decrease the occurrence or severity of antipsychotic treatment-emergent extrapyramidal symptoms in humans."	1.34	The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms. ( Hemrick-Luecke, SK; Hsu, MA; Johnson, BG; Noone, S; Rasmussen, K; Thompson, LK, 2007)
" In addition, adverse events were also evaluated."	1.34	[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO]. ( Agoston, T; István, S; Tamás, T; Zoltán, J, 2007)
"Haloperidol was provided at a moderate dose (10 mg/day)."	1.33	Aripiprazole: new drug. Just another neuroleptic. ( , 2005)
"Risperidone-treated animals showed a catalepsy-like phenotype, which differed to that of haloperidol-treated rats, indicating that processes other than the anticipated dopaminergic mechanisms are underlying this phenomenon."	1.33	Behavioural effects of chronic haloperidol and risperidone treatment in rats. ( Dedova, I; Duffy, L; Karl, T; Matsumoto, I; O'brien, E, 2006)
" In view of a role of 5-hydroxytryptamine (5-HT; serotonin)-1A receptors in the elicitation of EPS, the present study concerns pre- and postsynaptic responses to a selective 5-HT-1A receptor agonist, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) following acute and chronic administration of haloperidol in rats."	1.32	Enhancement of serotonin-1A receptor dependent responses following withdrawal of haloperidol in rats. ( Haleem, DJ; Khan, NH, 2003)
"Haloperidol-induced increase of striatal enkephalin mRNA is totally abolished in NGFI-B KO mice whereas the increase of neurotensin mRNA expression is reduced by 50%."	1.32	The transcription factor NGFI-B (Nur77) and retinoids play a critical role in acute neuroleptic-induced extrapyramidal effect and striatal neuropeptide gene expression. ( Beaudry, G; Ethier, I; Lévesque, D; Milbrandt, J; Rouillard, C; St-Hilaire, M, 2004)
" While typical antipsychotics are often switched to atypical agents when adverse effects become limiting, there is little preclinical information to support this strategy, both in terms of efficacy and side effects."	1.32	Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. ( Matsuoka, N; Mutoh, S; Shirakawa, K; Tada, M, 2004)
"Haloperidol was prescribed to control psychotic symptoms."	1.32	Potentiation of haloperidol neurotoxicity in acute hyperthyroidism: report of a case. ( Chu, H; Hsu, YD; Lin, JC, 2004)
"Catalepsy was measured in rats using both the cross-legged position test and the bar test."	1.31	Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy. ( Colpaert, FC; Kleven, MS; Koek, W; Prinssen, EP, 2000)
"Haloperidol-pretreated animals showed markedly impaired active avoidance, deficits which were improved by 2."	1.31	Low-dose clozapine pretreatment partially prevents haloperidol-induced deficits in conditioned active avoidance. ( Feldon, J; Murphy, CA, 2000)
"Risperidone-treated patients had a significantly higher DAI-10 score compared to haloperidol-treated patients."	1.31	Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). ( Edgell, E; García-Cabeza, I; Gómez, JC; González de Chavez, M; Sacristán, JA, 2001)
"Malignant syndrome is a disease characterized by high fever, extrapyramidal syndrome and dysautonomia recognized during or at the time of stopping administration of antipsychotic medication and it is the most severe and lethal side effect of antipsychotic medication."	1.30	[A case of malignant syndrome triggered by the use of haloperidol and chrorpromazine]. ( Fujimoto, K; Konishi, K; Kubota, M; Ogawa, H, 1997)
"Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors."	1.30	Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. ( Heinz, A; Knable, MB; Raedler, T; Weinberger, DR, 1997)
"2."	1.30	Evidence of sex related differences in the effects of calcium channel blockers on neuroleptic-induced catalepsy in mice. ( Amorim, SC; Costa, PG; Futuro-Neto, HA; Pires, JG; Ribeiro, CA; Saraiva, FP, 1999)
"This form of dystonia is called tardive dystonia to distinguish it from tardive dyskinesia."	1.29	[Tardive dystonia. A rare neuroleptic-induced disease picture]. ( Assion, HJ; Heinemann, F, 1994)
"Investigation revealed AIDS and a probable toxoplasmosis."	1.29	[Hemiballismus as initial manifestation of acquired immunodeficiency syndrome: a case report]. ( Albertin, MC; Fonseca, LC; Tedrus, GM, 1994)
"Remoxipride induced immediate catalepsy after high i."	1.29	Concentrations of remoxipride and its phenolic metabolites in rat brain and plasma. Relationship to extrapyramidal side effects and atypical antipsychotic profile. ( Lundström, J; Nilsson, LB; Ogren, SO, 1993)
"Fluoxetine (20 mg/day) was added for 7-10 days to stable doses of haloperidol given to eight psychotic patients."	1.28	Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. ( Baldessarini, RJ; Brotman, AW; Goff, DC; Midha, KK; Waites, M, 1991)
" These were haloperidol, clopenthixol, tefludazine, and setoperone, all tested in the dosage range of ."	1.28	Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates. ( Casey, DE, 1989)
" The authors examined the possibilities of a pharmacokinetic effect of alprazolam on neuroleptic plasma levels and of a clinical effect of alprazolam."	1.28	Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates. ( Angrist, B; Cooper, T; Douyon, R; Peselow, E; Rotrosen, J, 1989)
" However, by the 12th week of dosing with haloperidol all the monkeys showed a profound EPS characterized by limb extensions, head pushing, tongue protrusions and sometimes severe biting movements."	1.28	Acute extrapyramidal syndrome in Cebus monkeys: development mediated by dopamine D2 but not D1 receptors. ( Chipkin, RE; Coffin, VL; Latranyi, MB, 1989)
"Glycine was administered in an effort to facilitate endogenous glutamatergic transmission at the level of the N-methyl-D-aspartate (NMDA) receptor complex, since a glutamatergic deficiency in the pathophysiology of schizophrenia has been postulated."	1.28	Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. ( Banay-Schwartz, M; Cohen, CG; Deutsch, SI; Leighton, M; Rosse, RB; Scarcella, E; Theut, SK, 1989)
"Two typical recurrent episodes of neuroleptic malignant syndrome (NMS) in the same patient are described."	1.27	Recurrent neuroleptic malignant syndrome due to tiapride and haloperidol: the possible role of D-2 dopamine receptors. ( Hermesh, H; Huberman, M; Kott, E; Radvan, H, 1984)
"Haloperidol serum levels were determined by the recently developed radioimmunoassay technique to elucidate the relationship between serum levels and clinical effects and that between serum levels and adverse effects."	1.27	Monitoring of haloperidol serum levels and it's clinical significance. ( Fujii, Y; Ichikawa, K; Itoh, H; Iwamura, K; Tateyama, M; Yagi, G, 1984)
"We observed a case of NMS in which disseminated intravascular coagulation was a prominent feature."	1.27	Neuroleptic malignant syndrome complicated by disseminated intravascular coagulation. ( DiPette, DJ; Eles, GR; Songer, JE, 1984)
" The results support the hypothesis of a positive correlation between the CSF HVA and the hypokinetic-rigid side effect and a negative correlation between the pretherapeutic dopamine turnover and the risk of neuroleptic Parkinsonism."	1.27	Hypokinetic-rigid extrapyramidal side effects of neuroleptics: the relationship of the silent period in EMG and HVA and 5-HIAA in CSF. ( Baslo, A; Eroğlu, L; Hizal, A; Yazici, J; Yazici, O, 1986)
" Such variations have been attributed to individual metabolism, pharmacologic differences, and age--all of which may need careful consideration in prescribing an appropriate dosage regimen for a given patient."	1.27	Interpatient variations in antipsychotic therapy. ( Gershon, S; McIntyre, IM, 1985)
" Data were analyzed to determine the effect of anticholinergic prophylaxis, age, sex, and type and dosage of neuroleptic on the incidence of dystonic reactions."	1.27	Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study. ( Heiser, JF; Morrison, RL; Simpson, GM; Sramek, JJ, 1986)
"A case of neuroleptic malignant syndrome (NMS) with an abrupt onset was terminated quickly with i."	1.27	Resolution of neuroleptic malignant syndrome with dantrolene sodium: case report. ( Jaffe, JH; Khan, A; Morrison, B; Nelson, WH, 1985)
" In contrast, haloperidol failed to exert a similar effect at a dosage (1."	1.27	Conditioned taste aversion to chlorpromazine, but not to haloperidol. ( Giardini, V, 1985)
"A case illustrating the worsening of a patient's schizophrenic symptoms following haloperidol dosage increases in presented."	1.26	Psychotic exacerbation with haloperidol. ( Lee, D; Sramek, JJ; Tornatore, FL, 1981)
" A long-term use of haloperidol did not exert any significant influence on the cortical function of the formation of conditioned reflexes, but there was a retardation in the fixation of new conditioned reflexes after 6 months of drug administration."	1.26	[Pathophysiologic and morphologic changes in the central nervous system following long-term haloperidol administration]. ( Bobritskaia, ZM; Gorbatko, LG; Gordienko, ZhP; Litvinova, NM, 1981)
"Chronic schizophrenic patients were maintained for six months on a dosage of haloperidol adjusted to give optimum clinical effect."	1.26	Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia. ( Bishop, M; Coppen, A; Rao, VA, 1980)
" A long-term use of the preparation leads to development of habituation, while its cessation--to symptoms similar to withdrawal."	1.26	[Influence of extrapyramidal disorders induced by haloperidol on phenamine stereotypy and the effects of schizophrenic patients' serum (experimental study)]. ( Bobritskaia, ZM; Gorbatko, LG; Litvinova, NM; Stoliarov, GV, 1977)
"The effect of various antipsychotic drugs on the blockade of dopaminergic receptors in striatum and limbic forebrain was examined by establishing dose-response curves for the increase in HVA and for the antagonism of d-amphetamine-induced rotation in rats with unilateral lesions of the substantia nigra."	1.25	On the significance of the increase in homovanillic acid (HVA) caused by antipsychotic drugs in corpus striatum and limbic forebrain. ( Dingell, JV; Hill, H; Robinson, SE; Setler, P; Stawarz, RJ; Sulser, F, 1975)

Research

Studies (324)

Authors

Clinical Trials (16)

Trial Overview

Trial Outcomes

Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)

Timeframe	Studies, this research(%)	All Research%
pre-1990	135 (41.67)	18.7374
1990's	79 (24.38)	18.2507
2000's	83 (25.62)	29.6817
2010's	27 (8.33)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Kongsamut, S	1
Roehr, JE	1
Cai, J	1
Hartman, HB	1
Weissensee, P	1
Kerman, LL	1
Tang, L	1
Sandrasagra, A	1
Sikazwe, DM	1
Li, S	1
Lyles-Eggleston, M	1
Ablordeppey, SY	1
Lange, JH	1
Reinders, JH	1
Tolboom, JT	1
Glennon, JC	1
Coolen, HK	1
Kruse, CG	1
Zun, LS	1
Arora, D	1
Mudgal, J	1
Nampoothiri, M	1
Mallik, SB	1
Kinra, M	1
Hall, S	1
Anoopkumar-Dukie, S	1
Grant, GD	1
Rao, CM	1
Zivković, M	1
Mihaljević-Peles, A	1
Bozina, N	2
Sagud, M	1
Nikolac-Perkovic, M	1
Vuksan-Cusa, B	1
Muck-Seler, D	1
Bošković, M	1
Grabnar, I	1
Terzič, T	1
Kores Plesničar, B	1
Vovk, T	1
Gassó, P	1
Papagianni, K	1
Mas, S	1
de Bobadilla, RF	1
Arnaiz, JA	1
Bernardo, M	2
Lafuente, A	1
Crowley, JJ	2
Ashraf-Khorassani, M	1
Castagnoli, N	1
Sullivan, PF	1
Powell, A	1
Flynn, P	1
Rischbieth, S	1
McKellar, D	1
Kinon, BJ	3
Kollack-Walker, S	2
Jeste, D	1
Gupta, S	1
Chen, L	1
Case, M	2
Chen, J	1
Stauffer, V	1
Schrijver, EJ	1
de Vries, OJ	1
Verburg, A	1
de Graaf, K	1
Bet, PM	1
van de Ven, PM	1
Kamper, AM	1
Diepeveen, SH	1
Anten, S	1
Siegel, A	1
Kuipéri, E	1
Lagaay, AM	1
van Marum, RJ	1
van Strien, AM	1
Boelaarts, L	1
Pons, D	1
Kramer, MH	1
Nanayakkara, PW	1
Asadollahi, S	1
Heidari, K	1
Hatamabadi, H	1
Vafaee, R	1
Yunesian, S	1
Azadbakht, A	1
Mirmohseni, L	1
Shimizu, S	3
Mizuguchi, Y	2
Sobue, A	1
Fujiwara, M	1
Morimoto, T	1
Ohno, Y	3
McClay, JL	1
Vunck, SA	1
Batman, AM	1
Vann, RE	1
Beardsley, PM	1
van den Oord, EJ	1
Zheng, W	1
Li, XB	1
Xiang, YQ	1
Zhong, BL	1
Chiu, HF	1
Ungvari, GS	1
Ng, CH	1
Lok, GK	1
Xiang, YT	1
Tatara, A	2
Masui, A	1
Tamura, M	1
Minamimoto, S	1
Ochiai, M	1
Mizobe, Y	1
Šimić, I	1
Potočnjak, I	1
Kraljičković, I	1
Stanić Benić, M	1
Čegec, I	1
Juričić Nahal, D	1
Ganoci, L	1
Kim, E	1
Correll, CU	1
Mao, L	1
Starr, HL	1
Alphs, L	1
Malik, T	1
Hasan, S	1
Pervez, S	1
Fatima, T	1
Haleem, DJ	3
Popov, MIu	1
Bonham, C	1
Abbott, C	1
Min, JH	1
Youn, YC	1
Batool, F	1
Starkey, SR	1
Morrisey, JK	1
Hickam, HD	1
Albright, JD	1
Lynch, MJ	1
Peuskens, J	2
Gillain, B	1
De Graeve, D	1
Van Vleymen, B	1
Albert, A	1
Castle, DJ	1
Udristoiu, T	1
Kim, CY	1
Sarosi, A	1
Pidrman, V	1
Omar, AN	1
Rosales, JI	1
Melamed, Y	1
Isik, T	1
Karagianis, J	1
Treuer, T	1
Satterthwaite, TD	1
Wolf, DH	1
Rosenheck, RA	1
Gur, RE	2
Caroff, SN	2
Han, M	1
Huang, XF	1
Deng, C	1
Glick, ID	2
Mankoski, R	2
Eudicone, JM	1
Marcus, RN	4
Tran, QV	1
Assunção-Talbott, S	1
Imaki, J	1
Docherty, JP	1
Baker, RA	1
Eudicone, J	2
Mathew, S	1
McQuade, RD	2
González-Lugo, OE	1
Ceballos-Huerta, F	1
Jiménez-Capdeville, ME	1
Arankowsky-Sandoval, G	1
Góngora-Alfaro, JL	1
Stauffer, VL	1
Conley, R	1
Ascher-Svanum, H	1
Kane, J	1
McEvoy, J	2
Lieberman, J	1
Trevizol, F	1
Benvegnú, DM	1
Barcelos, RC	1
Pase, CS	1
Segat, HJ	1
Dias, VT	1
Dolci, GS	1
Boufleur, N	1
Reckziegel, P	1
Bürger, ME	1
Yamamoto, Y	1
Shioda, N	1
Owada, Y	1
Fukunaga, K	1
Veselinović, T	1
Schorn, H	1
Vernaleken, I	1
Schiffl, K	1
Hiemke, C	2
Zernig, G	1
Gur, R	1
Gründer, G	1
Greenbaum, L	1
Lifschytz, T	1
Zozulinsky, P	1
Broner, EC	1
Slonimsky, A	1
Kohn, Y	1
Lerer, B	1
Klemp, M	1
Tvete, IF	1
Skomedal, T	1
Gaasemyr, J	1
Natvig, B	1
Aursnes, I	1
Morales, I	1
Fuentes, A	1
Ballaz, S	1
Obeso, JA	1
Rodriguez, M	1
Thomsen, TW	1
Brown, DF	1
Nadel, ES	1
Inada, T	2
Yagi, G	2
Miura, S	1
Kane, JM	6
Carson, WH	3
Saha, AR	1
Ingenito, GG	1
Zimbroff, DL	2
Ali, MW	1
Beasley, CM	4
Tanaka, Y	1
Walker, DJ	1
de Haan, L	1
van Bruggen, M	1
Lavalaye, J	1
Booij, J	1
Dingemans, PM	1
Linszen, D	1
Meibach, RC	1
Wynchank, D	1
Berk, M	1
Khan, NH	1
Lieberman, JA	4
Tollefson, G	1
Tohen, M	4
Green, AI	1
Kahn, R	1
Perkins, D	1
Sharma, T	2
Zipursky, R	3
Wei, H	2
Hamer, RM	2
Carlson, CD	1
Cavazzoni, PA	2
Berg, PH	2
Torner, C	1
Herrera-Estrella, M	1
Gutiérrez, JA	1
Aguilar-Roblero, R	1
BORENSTEIN, P	2
DABBAH, M	1
BLES, G	2
Ethier, I	1
Beaudry, G	1
St-Hilaire, M	1
Milbrandt, J	1
Rouillard, C	1
Lévesque, D	1
Skrobik, YK	1
Bergeron, N	1
Dumont, M	1
Gottfried, SB	1
Wright, P	1
Lindborg, SR	1
Birkett, M	1
Meehan, K	1
Jones, B	1
Alaka, K	1
Ferchland-Howe, I	1
Pickard, A	1
Taylor, CC	1
Roth, J	1
Battaglia, J	1
Bitter, I	2
Chouinard, G	5
Morris, PL	1
Breier, A	1
Akhondzadeh, S	2
Erfani, S	1
Mohammadi, MR	1
Tehrani-Doost, M	2
Amini, H	2
Gudarzi, SS	1
Yasamy, MT	1
Tada, M	1
Shirakawa, K	1
Matsuoka, N	1
Mutoh, S	1
Henkel, V	1
Mergl, R	1
Schäfer, M	1
Rujescu, D	1
Möller, HJ	5
Hegerl, U	1
Keefe, RS	1
Seidman, LJ	1
Christensen, BK	1
Sitskoorn, MM	1
Lewine, RR	1
Yurgelun-Todd, DA	1
Gur, RC	1
Tollefson, GD	4
Sanger, TM	2
Dagaev, SG	1
Kosmachev, AB	1
Filko, OA	1
Kubarskaya, LG	1
Khrabrova, AV	1
Beliaev, VA	1
Podosinovikova, NP	1
Libman, NM	1
Sanotskii, VI	1
Dolgo-Saburov, VB	1
Chu, H	1
Lin, JC	1
Hsu, YD	1
Scherer, J	3
Dobmeier, P	1
Kuhn, K	1
Schmaus, W	1
Buchanan, RW	1
Ball, MP	1
Weiner, E	1
Kirkpatrick, B	1
Gold, JM	1
McMahon, RP	1
Carpenter, WT	1
Honer, WG	1
Kopala, LC	1
Rabinowitz, J	1
Marder, SR	5
Sayers, SL	1
Campbell, EC	1
Kondrich, J	1
Mann, SC	1
Cornish, J	1
O'Brien, C	1
Ciudad, A	1
Gutiérrez, M	1
Cañas, F	1
Gibert, J	1
Gascón, J	1
Carrasco, JL	1
Bobes, J	1
Gómez, JC	3
Alvarez, E	1
Matsui-Sakata, A	1
Ohtani, H	1
Sawada, Y	1
Park, S	1
Ross-Degnan, D	1
Adams, AS	1
Sabin, J	1
Kanavos, P	1
Soumerai, SB	1
Perquin, LN	1
Kryzhanovskaya, LA	1
Briggs, SD	1
Roddy, TE	1
Artaloytia, JF	1
Arango, C	1
Lahti, A	1
Sanz, J	1
Pascual, A	1
Cubero, P	1
Prieto, D	1
Palomo, T	1
Bloch, MH	1
Landeros-Weisenberger, A	1
Kelmendi, B	1
Coric, V	1
Bracken, MB	1
Leckman, JF	1
Gharabawi, GM	1
Bossie, CA	1
Zhu, Y	1
Karl, T	1
Duffy, L	1
O'brien, E	1
Matsumoto, I	1
Dedova, I	1
Guo, SL	1
Lin, CJ	1
Huang, HH	1
Chen, LK	1
Sun, WZ	1
Tariot, PN	1
Schneider, L	1
Katz, IR	1
Mintzer, JE	1
Street, J	1
Copenhaver, M	1
Williams-Hughes, C	1
Lee, SY	1
Kim, YG	1
Kim, HG	1
Kim, JW	1
Andrezina, R	1
Josiassen, RC	1
Oren, DA	1
Manos, G	1
Stock, E	1
Iwamoto, T	1
Dziewas, R	1
Warnecke, T	1
Schnabel, M	1
Ritter, M	1
Nabavi, DG	1
Schilling, M	1
Ringelstein, EB	1
Reker, T	1
Nasrallah, HA	1
Brecher, M	1
Paulsson, B	1
Milajerdi, MR	1
Limosin, F	1
Timdahl, K	1
Carlsson, A	3
Stening, G	1
Crandall, DT	1
Pikalov, A	1
Swyzen, W	1
Rasmussen, K	1
Hsu, MA	1
Noone, S	1
Johnson, BG	1
Thompson, LK	1
Hemrick-Luecke, SK	1
Villari, V	1
Rocca, P	1
Fonzo, V	1
Montemagni, C	1
Pandullo, P	1
Bogetto, F	1
Kumra, S	1
Oberstar, JV	1
Sikich, L	1
Findling, RL	1
McClellan, JM	1
Vinogradov, S	1
Charles Schulz, S	1
Hazra, M	1
Mamo, DC	1
Remington, G	4
István, S	1
Agoston, T	1
Tamás, T	1
Zoltán, J	1
Owens, DC	1
Cesario, V	1
Liebman, J	1
Neale, R	1
Rovinskaia, SA	1
Revva, LI	1
Henderson, VW	1
Wooten, GF	1
Tornatore, FL	1
Lee, D	1
Sramek, JJ	2
Arnt, J	1
Christensen, AV	1
Hyttel, J	1
Ungvári, G	1
Czobor, P	2
Vitrai, J	1
Pethö, B	1
Stoudemire, A	1
Luther, JS	1
Knezevic, W	1
Mastaglia, FL	1
Lefroy, RB	1
Fisher, A	1
Silverstone, T	1
Levine, S	1
Freeman, HL	1
Dubini, A	1
Bismuth, C	3

Trial	Phase	Enrollment	Study Type	Start Date	Status
Early Pharmacological Intervention to Prevent Delirium: Haloperidol Prophylaxis in Older Emergency Department Patients[NCT01530308]	Phase 4	242 participants (Actual)	Interventional	2012-11-30	Completed
A Randomized Trial to Compare the Efficiency and Side Effect Between Olanzapine and Long-acting Paliperidone Palmitate Injection in Schizophrenia[NCT02918825]		100 participants (Actual)	Interventional	2016-09-01	Completed
Aripiprazole, Abilify Maintena Collaborative Clinical Protocol[NCT02717130]		9 participants (Actual)	Interventional	2016-06-08	Terminated (stopped due to The study was terminated due to lack of enrollment.)
Haloperidol vs Olanzapine for the Management of ICU Delirium: A Randomized Clinical Trial[NCT00833300]		200 participants (Anticipated)	Interventional	2008-06-30	Terminated
Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial.[NCT00564564]	Phase 4	21 participants (Actual)	Interventional	2006-01-31	Completed
Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)[NCT02422290]	Phase 1/Phase 2	5 participants (Actual)	Interventional	2015-03-31	Completed
An Open-Label Trial of Epidiolex in the Treatment of Obsessive Compulsive Disorder and Related Disorders: Proof of Concept Study[NCT04978428]	Phase 2	15 participants (Anticipated)	Interventional	2022-04-14	Recruiting
Open Label Study for the Use of Transcranial Ultrasound Treatment of Obsessive-Compulsive Disorder[NCT04775875]		30 participants (Anticipated)	Interventional	2020-12-01	Enrolling by invitation
Optimizing Rehabilitation for Phantom Limb Pain Using Mirror Therapy and Transcranial Direct Current Stimulation (tDCS)[NCT02487966]		132 participants (Actual)	Interventional	2015-07-31	Active, not recruiting
Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308]	Phase 2	20 participants (Actual)	Interventional	2007-07-31	Completed
I-123 Iodobenzamide (IBZM) SPECT Studies of D2 Receptor Distribution and Function in Patients With Schizophrenia and Normal Volunteers[NCT00001320]		265 participants	Observational	1991-10-31	Completed
Risperidone Versus Haloperidol Versus Placebo in the Treatment of Chronic Schizophrenia[NCT00249132]	Phase 3	523 participants (Actual)	Interventional		Completed
Treatment of Psychosis and Agitation in Alzheimer's Disease[NCT02129348]	Phase 2	77 participants (Actual)	Interventional	2014-06-30	Completed
Risk of Breakthrough Symptoms On Antipsychotic Maintenance Medication When Remitted Patients Are Treated With Long-Acting Injectable Medications[NCT05473741]		180 participants (Anticipated)	Observational	2023-01-09	Recruiting
The Safety And Efficacy Of Risperdal� (Risperidone) Versus Placebo Versus Haloperidol As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder[NCT00253149]	Phase 3	158 participants (Actual)	Interventional		Completed
A Randomized, Double-Blind, Comparison of the Efficacy and Safety of Risperidone Versus Risperidone Combined With Low Dose of Haloperidol in the Treatment of Schizophrenic Disorder[NCT00998608]	Phase 4	88 participants (Actual)	Interventional	2007-08-31	Terminated (stopped due to terminated)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The CY-BOCS is a semi-structured measure of OCD severity with excellent inter-rater reliability, internal consistency, and test-retest reliability. It is validated in those starting at age 7 and used in studies up to age 20. The CYBOCS differs from the adult YBOCS only in its use of simpler language. The CY-BOCS consists of 10 items which are summed up to derive the total CY-BOCS score. The total score ranges from 0-40 with higher scores indicating greater severity of OCD symptoms. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported

Clinical Global Impressions - Severity Scale (CGI-S)

Intervention	score on a scale (Mean)
	CY-BOCS Baseline	CY-BOCS Day 14
Ketamine Treatment Group	29.00	26.20

The CGI-S is a clinician rated 7-point rating scale for the severity of a participant's illness relative to the clinician's experience of working with this particular population. The score ranges from 1-7 with higher scores indicating greater illness severity. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported

OCD Visual Analogue Scale (OCD-VAS)

Intervention	score on a scale (Mean)
	CGI-S Baseline	CGI-S Day 14
Ketamine Treatment Group	5.80	5.00

"The OCD-VAS is a one-item unipolar scale to assess OCD symptoms over a rapid time frame (No obsessions to Constant obsessions). The scale ranges from 0-10 with higher scores indicating higher presence of obsessions." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported

Yale-Brown Obsessive Compulsive Challenge Scale (Y-BOCCS)

Intervention	score on a scale (Mean)
	OCD-VAS Baseline	OCD-VAS Day 14
Ketamine Treatment Group	5.00	5.00

"The Y-BOCCS is self-report scale which assesses OCD symptoms on a 5-point likert scale (None to Extreme). It consists of 10 items which are summed up to derive the total Y-BOCCS score. The total score ranges from 0-40 with higher scores indicating higher prevalence of OCD symptoms." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported

Changes in the Visual Analog Scale for Phantom Limb Pain

Intervention	score on a scale (Mean)
	Y-BOCCS Baseline	Y-BOCCS Day 14
Ketamine Treatment Group	18.25	16.50

The primary endpoint will be the severity of pain measured by changes in PLP from baseline to 4 weeks (value at 4 weeks minus value at baseline), as indexed by a Visual Analog Scale (VAS). The VAS pain scale is a simple 10- point scale (0 = ''no pain'', 10 = ''pain as bad as you can imagine''). Since we are using a difference, smaller values (negative) represent a better outcome. (NCT02487966)
Timeframe: 4 weeks

Changes in the Visual Analog Scale for Phantom Limb Sensation

Intervention	units on a scale (Mean)
Active tDCS and Active Mirror Therapy	-2.84
Active tDCS and Sham Mirror Therapy	-3.35
Sham tDCS and Active Mirror Therapy	-1.78
Sham tDCS and Sham Mirrory Therapy	-2.58

The endpoint will be the severity of pain measured by changes in Phantom Limb Sensation from baseline to 4 weeks (value at 4 weeks minus value at baseline), as indexed by a Visual Analog Scale (VAS). The VAS Phantom Limb Sensation scale is a simple 10- point scale (0 = ''no Phantom Limb Sensation'', 10 = ''Phantom Limb Sensation as much as you can imagine''). Since we are using a difference, smaller values (negative) represent a better outcome. (NCT02487966)
Timeframe: 4 weeks

Changes in the Visual Analog Scale for Stump Pain

Intervention	units on a scale (Mean)
Active tDCS and Active Mirror Therapy	-1.86
Active tDCS and Sham Mirror Therapy	-2.55
Sham tDCS and Active Mirror Therapy	-1.35
Sham tDCS and Sham Mirrory Therapy	-2.83

The endpoint will be the severity of pain measured by changes in Stump Pain from baseline to 4 weeks (value at 4 weeks minus value at baseline), as indexed by a Visual Analog Scale (VAS). The VAS Phantom Limb Stump Pain scale is a simple 10- point scale (0 = ''no Phantom Limb Stump Pain'', 10 = ''Phantom Limb Stump Pain as bad as you can imagine''). Since we are using a difference, smaller values (negative) represent a better outcome. (NCT02487966)
Timeframe: 4 weeks

"Number of Patients With Improved or Minimally Improved in Clinical Global Impression-Improvement (CGI) Scale"

Intervention	units on a scale (Mean)
Active tDCS and Active Mirror Therapy	-1.31
Active tDCS and Sham Mirror Therapy	-1.9
Sham tDCS and Active Mirror Therapy	-0.91
Sham tDCS and Sham Mirrory Therapy	-0.96

"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks

"Number of Patients With Much Improved or Very Much Improved on Clinical Global Impression-Improvement (CGI) Scale"

Intervention	participants (Number)
Active	2
Sham	8

Motor Cortex Excitability Normalization-Left Motor Threshold

Intervention	participants (Number)
Active	1
Sham	0

Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks

Motor Cortex Excitability Normalization-Right Motor Threshold

Intervention	µV (Mean)
Active	56.5
Sham	63.8

Yale Global Tic Severity Scale (Y-GTSS)

Intervention	µV (Mean)
Active	56
Sham	59.8

Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks

Basic Activities of Daily Living (BADL)

Intervention	units on a scale (Mean)
Active	29.5
Sham	31.5

Basic Activities of Daily Living with items for 6 functions: bathing, dressing, toileting, transferring, continence, and feeding. Each item is scored as unimpaired=1, impaired=0. Total score is the measure used, range 0-6; higher scores indicate better functioning. (NCT02129348)
Timeframe: Assessed at Week 0, Week2, Week 4, Week 6, Week 8, Week 10, Week 12

Change in Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	0.3
Placebo Group	0.1

Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain is the measure used that combines symptoms of agitation and aggression. Frequency X Severity rating score, range 0-12. Higher score indicates more agitation and aggressive behavior. (NCT02129348)
Timeframe: Assessed at screening, Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12

Clinical Global Impression (CGI) Behavior Change

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	3.2
Placebo Group	2.5

Clinical Global Impression (CGI) Behavior Change score is the measure used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Scores ranging from 1-3 indicate improvement. Only patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12

Clinical Responder Defined as a 30% Decrease in NPI Core Score (Sum Score of NPI Domains of Agitation/Aggression, Delusions and Hallucinations) Together With a Clinical Global Impression (CGI) Behavior Change Score of 1 or 2

Intervention	Participants (Count of Participants)
Lithium Treatment Group	12
Placebo Group	8

The patient is classified as a responder (score=1) if both criteria are met or as a non-responder (score=0) if both criteria are not met. The first criterion to determine responder status, NPI core score, has a scoring range 0-36; each of the three component scores for symptoms of agitation/aggression, delusions and hallucinations has a scoring range 0-12. For each symptom and the total score, higher score indicates more symptoms. The second criterion to determine responder status, Clinical Global Impression (CGI), is used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Only patients who met both criteria, assessed as change compared to baseline, were counted as responders; all other patients were non-responders. Patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12

Folstein Mini-Mental Status Exam

Intervention	Participants (Count of Participants)
Lithium Treatment Group	12
Placebo Group	7

30 item questionnaire used to assess degree of cognitive impairment. Orientation, registration, attention/calculation, recall, language, repetitions and commands are assessed. Total score is the measure used; range 0-30, higher scores indicate better global cognitive function. (NCT02129348)
Timeframe: Assessed at Screening, Week 12

Severe Impairment Battery

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	0.9
Placebo Group	0.9

Neuropsychological test used to assess a patient's cognitive ability. The patient is asked to complete small tasks such as drawing shapes and printing their name. They are also asked to remember certain names and objects, such as a cup and a spoon, and the evaluator's first name. Total score is the measure used; range 0-100, higher scores indicate better cognition. (NCT02129348)
Timeframe: Assessed at Week 0, Week 12

Simpson-Angus Scale

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	2.1
Placebo Group	-0.0

Simpson Angus Scale for Extrapyramidal Sign requires in-person examination to assess gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor, and salivation. Total score is the measure used, range 0-40; higher scores indicate increased severity of signs. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12

Treatment Emergent Signs and Symptoms

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	-0.0
Placebo Group	0.0

Treatment Emergent Symptom Scale that covers 26 somatic symptoms, each rated as present (score=1) or absent (score=0). Total score is the measure used with scoring range 0-26; higher scores indicate more somatic symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12

Young Mania Rating Scale

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	0.6
Placebo Group	0.7

Young Mania Rating Scale total score is the measure used to assess symptoms that occur in mania; each item is a symptom that is rated for severity. Scoring range 0-60; higher scores indicate more severe symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12

Zarit Caregiver Burden Interview

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	3.1
Placebo Group	1.1

Zarit Caregiver Burden Interview with the caregiver asked to rank 22 items on a scale with responses for each item from 'never' (score 0) to 'nearly always' (score 4). Total score is the measure used; range 0-88 with higher scores indicating greater caregiver burden. (NCT02129348)
Timeframe: Assessed at Week 0, Week 4, Week 8, Week 10, Week 12

Article	Year
Evidence-Based Review Of Pharmacotherapy For Acute Agitation. Part 2: Safety. The Journal of emergency medicine, 2018, Volume: 54, Issue:4 Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Emergency Service, Hospital; Evidence	2018
Aripiprazole for Tourette's syndrome: a systematic review and meta-analysis. Human psychopharmacology, 2016, Volume: 31, Issue:1 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Child; Haloperidol; Humans;	2016
Are second generation antipsychotics a distinct class? Journal of psychiatric practice, 2008, Volume: 14, Issue:4 Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Cognition Disorders; Haloperidol; Humans; Q	2008
A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. The Journal of clinical psychiatry, 2008, Volume: 69, Issue:12 Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cholinergic Antagonists; Drug Therapy, Combinat	2008
[Regulation of dopaminergic neuronal activity by heart-type fatty acid binding protein in the brain]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2011, Volume: 131, Issue:4 Topics: Acetylcholine; Animals; Basal Ganglia Diseases; Brain; Catalepsy; Dopamine; Dopamine Antagonists; Fa	2011
A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo. Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:6 Topics: Antipsychotic Agents; Basal Ganglia Diseases; Bayes Theorem; Haloperidol; Humans; Randomized Control	2011
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. The Journal of clinical psychiatry, 2003, Volume: 64, Issue:8 Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cholinergic Ant	2003
Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. The Journal of clinical psychiatry, 2006, Volume: 67, Issue:1 Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Bipolar Disorder; Brief Psychi	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive	2006
Neuroleptic-induced dysphagia: case report and literature review. Dysphagia, 2007, Volume: 22, Issue:1 Topics: Antipsychotic Agents; Basal Ganglia Diseases; Deglutition; Deglutition Disorders; Haloperidol; Human	2007
[The use of atypical antipsychotics in the long-term care of schizophrenia]. L'Encephale, 2006, Volume: 32 Pt 3 Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine;	2006
An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms. Human psychopharmacology, 2007, Volume: 22, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Chlorproma	2007
Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophrenia research, 2007, Volume: 95, Issue:1-3 Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Double-Blind Method; Halo	2007
Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophrenia bulletin, 2008, Volume: 34, Issue:1 Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Disorders of Excessive Som	2008
Dopamine receptors in the basal ganglia: relevance to Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1993, Volume: 8, Issue:3 Topics: Basal Ganglia; Basal Ganglia Diseases; Brain; Clozapine; Dopamine Agents; Dopamine D2 Receptor Antag	1993
Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology, 1996, Volume: 124, Issue:1-2 Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Animal; Biogenic Amines; Brain; Clo	1996
Dosing the antipsychotic medication olanzapine. The Journal of clinical psychiatry, 1997, Volume: 58 Suppl 10 Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dose-Respons	1997
The relationship of pharmacology to side effects. The Journal of clinical psychiatry, 1997, Volume: 58 Suppl 10 Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; D	1997
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia research, 1999, Jan-04, Volume: 35, Issue:1 Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dibenzothiazepines; Double-Blind Meth	1999
Antiparkinson drugs in paranoid schizophrenia. North Carolina medical journal, 1979, Volume: 40, Issue:5 Topics: Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Haloperidol; Humans; Perphenazin	1979
Significance of neurochemical parameters in the preclinical evaluation of neuroleptic drugs. Pharmacology & therapeutics. Part B: General & systematic pharmacology, 1979, Volume: 5, Issue:1-3 Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Brain Chemistry; Clozapine; Corpus Striatum;	1979
The pathogensis and medical treatment of extrapyramidal disease. The Medical clinics of North America, 1979, Volume: 63, Issue:4 Topics: Adult; Athetosis; Basal Ganglia Diseases; Caudate Nucleus; Chorea; Corpus Striatum; Dopamine; Dopami	1979
Overview: efficacy and safety of the rapid neuroleptization method with injectable haloperidol. The American journal of psychiatry, 1979, Volume: 136, Issue:3 Topics: Acute Disease; Administration, Oral; Basal Ganglia Diseases; Bipolar Disorder; Clinical Trials as To	1979
Aging and the extrapyramidal system. The Medical clinics of North America, 1976, Volume: 60, Issue:6 Topics: Aged; Aging; Basal Ganglia Diseases; Chlorpromazine; Chorea; Dopamine; Frontal Lobe; Gait; Haloperid	1976
Intravenous haloperidol for tranquilization in critical care patients: a review and critique. AACN clinical issues in critical care nursing, 1991, Volume: 2, Issue:4 Topics: Aged; Basal Ganglia Diseases; Critical Illness; Death, Sudden; Female; Haloperidol; Humans; Infusion	1991
Blood levels of neuroleptics: state of the art. The Journal of clinical psychiatry, 1985, Volume: 46, Issue:5 Pt 2 Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Dose-Response Relationship, Drug; Drug	1985
Nervous mechanisms involved in experimentally induced extrapyramidal disturbances. Confinia neurologica, 1974, Volume: 36, Issue:4-6 Topics: Animals; Basal Ganglia Diseases; Benztropine; Brain; Cats; Caudate Nucleus; Cerebellar Nuclei; Chlor	1974
Drug-induced extrapyramidal disorders. Research publications - Association for Research in Nervous and Mental Disease, 1972, Volume: 50 Topics: Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Benztropine; Dihydroxyphenylalanine; Dopa	1972

Article	Year
Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers. Pharmacogenomics, 2013, Volume: 14, Issue:13 Topics: Adult; Area Under Curve; Basal Ganglia Diseases; Cross-Over Studies; Cytochrome P-450 CYP2D6; Double	2013
Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics. Journal of geriatric psychiatry and neurology, 2015, Volume: 28, Issue:1 Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Female; Halo	2015
Efficacy and safety of haloperidol prophylaxis for delirium prevention in older medical and surgical at-risk patients acutely admitted to hospital through the emergency department: study protocol of a multicenter, randomised, double-blind, placebo-control BMC geriatrics, 2014, Aug-28, Volume: 14 Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Delirium; Double-Blind Method	2014
Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, double-blind, parallel-group trial. International clinical psychopharmacology, 2015, Volume: 30, Issue:3 Topics: Adult; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Female;	2015
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia. CNS spectrums, 2016, Volume: 21, Issue:6 Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazep	2016
[The use of nifedipine as a corrector of extrapyramidal side-effects of classical neuroleptics]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2008, Volume: 108, Issue:6 Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Female; Haloperidol; Humans; Male; Nifedipine;	2008
Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia. Schizophrenia research, 2010, Volume: 120, Issue:1-3 Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Basal Ganglia Dis	2010
Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry research, 2011, May-15, Volume: 187, Issue:1-2 Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Metho	2011
Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers. Psychopharmacology, 2011, Volume: 218, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dopamine; Female; Haloperidol; Hu	2011
Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophrenia research, 2002, Oct-01, Volume: 57, Issue:2-3 Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Female; H	2002
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. The Journal of clinical psychiatry, 2002, Volume: 63, Issue:9 Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Doubl	2002
Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. International clinical psychopharmacology, 2003, Volume: 18, Issue:1 Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Diagnosis, Differential; Femal	2003
Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. The American journal of psychiatry, 2003, Volume: 160, Issue:2 Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Corpus Striatum; D	2003
Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial. Human psychopharmacology, 2003, Volume: 18, Issue:4 Topics: Acute Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Basal Ganglia Disease	2003
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. The American journal of psychiatry, 2003, Volume: 160, Issue:8 Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Metho	2003
Diurnal variations of extrapyramidal symptoms induced by haloperidol in schizophrenic subjects. The international journal of neuropsychopharmacology, 2003, Volume: 6, Issue:3 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Circadian Rhythm; Cros	2003
Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive care medicine, 2004, Volume: 30, Issue:3 Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; De	2004
Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2003, Volume: 48, Issue:11 Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatr	2003
Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. Journal of clinical pharmacy and therapeutics, 2004, Volume: 29, Issue:2 Topics: Autistic Disorder; Basal Ganglia Diseases; Child; Child, Preschool; Cyproheptadine; Double-Blind Met	2004
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. The American journal of psychiatry, 2004, Volume: 161, Issue:6 Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cognition Disorder	2004
[Incidence of rigor during treatment with flupentixol decanoate in comparison to risperidone]. Psychiatrische Praxis, 2004, Volume: 31 Suppl 1 Topics: Adult; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; Body Weight; Cross-Sectio	2004
Olanzapine treatment of residual positive and negative symptoms. The American journal of psychiatry, 2005, Volume: 162, Issue:1 Topics: Adult; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Weight;	2005
Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. Journal of psychopharmacology (Oxford, England), 2005, Volume: 19, Issue:3 Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Double-Bli	2005
Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. The Journal of clinical psychiatry, 2005, Volume: 66, Issue:5 Topics: Administration, Oral; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dibenzothiazepines; Femal	2005
Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. The Journal of nervous and mental disease, 2005, Volume: 193, Issue:6 Topics: Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Addictive; Benzodiazepines; Cocaine-Related	2005
Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study. Progress in neuro-psychopharmacology & biological psychiatry, 2005, Volume: 29, Issue:6 Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Demography; Dose-Response Rela	2005
Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. The American journal of psychiatry, 2006, Volume: 163, Issue:3 Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Behavioral Symptoms; Brief Psychiat	2006
Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2006, Volume: 14, Issue:9 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Bri	2006
Pharmacokinetic parameters of bromperidol in Korean subjects. Human psychopharmacology, 2006, Volume: 21, Issue:6 Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A	2006
Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology, 2006, Volume: 188, Issue:3 Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Dyskinesia Agents; Antipsychotic Agents	2006
Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar disorders, 2006, Volume: 8, Issue:5 Pt 1 Topics: Acute Disease; Adult; Allopurinol; Antimanic Agents; Basal Ganglia Diseases; Bipolar Disorder; Doubl	2006
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Progress in neuro-psychopharmacology & biological psychiatry, 2008, Feb-15, Volume: 32, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Basal Ganglia Disea	2008
Zetidoline, a new antipsychotic. First controlled trial in acute schizophrenia. The British journal of psychiatry : the journal of mental science, 1984, Volume: 145 Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trial	1984
Haloperidol: a quarter century of experience. The Journal of clinical psychiatry, 1983, Volume: 44, Issue:12 Topics: Aged; Basal Ganglia Diseases; Bipolar Disorder; Clinical Trials as Topic; Dosage Forms; Drug Adminis	1983
A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. European archives of psychiatry and clinical neuroscience, 1995, Volume: 245, Issue:1 Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Haloperidol; Hum	1995
Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology, 1995, Volume: 118, Issue:1 Topics: Adult; Akathisia, Drug-Induced; Basal Ganglia Diseases; Clozapine; Dyskinesia, Drug-Induced; Female;	1995
Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry, 1993, Volume: 26, Issue:4 Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Fema	1993
The tolerability and efficacy of the atypical neuroleptic remoxipride compared with clozapine and haloperidol in acute schizophrenia. Acta psychiatrica Scandinavica. Supplementum, 1994, Volume: 380 Topics: Adult; Basal Ganglia Diseases; Clozapine; Cognition; Double-Blind Method; Drug Tolerance; Emotions;	1994
Aggression in the demented patient: a double-blind study of loxapine versus haloperidol. International clinical psychopharmacology, 1993,Summer, Volume: 8, Issue:2 Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Basal Ganglia Diseases; Dementia; Dementia,	1993
A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. The American journal of psychiatry, 1996, Volume: 153, Issue:2 Topics: Adult; AIDS Dementia Complex; Basal Ganglia Diseases; Chlorpromazine; Delirium; Double-Blind Method;	1996
A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. The Journal of clinical psychiatry, 1996, Volume: 57, Issue:4 Topics: Acute Disease; Administration, Oral; Adult; Basal Ganglia Diseases; Bipolar Disorder; Haloperidol; H	1996
Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette's syndrome. Biological psychiatry, 1996, Nov-15, Volume: 40, Issue:10 Topics: Adolescent; Anti-Dyskinesia Agents; Basal Ganglia Diseases; Child; Cross-Over Studies; Double-Blind	1996
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. The American journal of psychiatry, 1997, Volume: 154, Issue:4 Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depre	1997
Symptom change and extrapyramidal side effects during acute haloperidol treatment in chronic geriatric schizophrenics. Psychopharmacology bulletin, 1997, Volume: 33, Issue:1 Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Disease Prog	1997
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. The American journal of psychiatry, 1997, Volume: 154, Issue:6 Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Chro	1997
Extrapyramidal symptoms in patients treated with risperidone. Journal of clinical psychopharmacology, 1997, Volume: 17, Issue:3 Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dopamine Antagonists; Double-Blind Method; Fema	1997
Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. The Journal of clinical psychiatry, 1997, Volume: 58, Issue:5 Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Drug Admi	1997
Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. The American journal of psychiatry, 1997, Volume: 154, Issue:8 Topics: Adolescent; Basal Ganglia Diseases; Child; Cross-Over Studies; Double-Blind Method; Drug Administrat	1997
Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes. Psychiatry research, 1997, Jun-16, Volume: 71, Issue:1 Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Depression; Female; Haloperidol; Humans; Male;	1997
Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients. Neuropsychobiology, 1997, Volume: 36, Issue:2 Topics: Adult; Aged; Anti-Dyskinesia Agents; Antipsychotic Agents; Basal Ganglia Diseases; Biperiden; Chroni	1997
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. The Journal of clinical psychiatry, 1997, Volume: 58, Issue:12 Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Double-Blind Meth	1997
Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. European archives of psychiatry and clinical neuroscience, 1997, Volume: 247, Issue:6 Topics: Adult; Antipsychotic Agents; Austria; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method;	1997
The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine. Psychopharmacology bulletin, 1998, Volume: 34, Issue:1 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Haloperidol; Humans; Mal	1998
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. The American journal of psychiatry, 1998, Volume: 155, Issue:7 Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases;	1998
Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry, 1998, Volume: 31, Issue:4 Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Biperiden; Brief Psychiatric Rating Scale; Chlo	1998
A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. The American journal of psychiatry, 1998, Volume: 155, Issue:11 Topics: Aged; Aggression; Alzheimer Disease; Ambulatory Care; Basal Ganglia Diseases; Brief Psychiatric Rati	1998
Haloperidol-induced extrapyramidal reaction: lack of protective effect by vitamin E. Psychopharmacology, 1998, Volume: 140, Issue:4 Topics: Adolescent; Adult; Antioxidants; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method;	1998
Olanzapine versus haloperidol treatment in first-episode psychosis. The American journal of psychiatry, 1999, Volume: 156, Issue:1 Topics: Age of Onset; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Ratin	1999
Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. Journal of clinical psychopharmacology, 1999, Volume: 19, Issue:3 Topics: Adult; Affective Disorders, Psychotic; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Co	1999
Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia. International clinical psychopharmacology, 1999, Volume: 14, Issue:4 Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dose-Response Relationship, Drug	1999
Risperidone in treatment-refractory schizophrenia. The American journal of psychiatry, 1999, Volume: 156, Issue:9 Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Brief Psychiatric Rating Scale; Cholinergic Ant	1999
Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. The Journal of clinical psychiatry, 1999, Volume: 60, Issue:12 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Child; Cholinergic Antagonist	1999
Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. The American journal of psychiatry, 2000, Volume: 157, Issue:4 Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Carbon Radioisotopes; Corpus Striat	2000
Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. Schizophrenia research, 2000, Dec-15, Volume: 46, Issue:2-3 Topics: Antipsychotic Agents; Basal Ganglia Diseases; Brief Psychiatric Rating Scale; Dose-Response Relation	2000
Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of clinical psychopharmacology, 2001, Volume: 21, Issue:4 Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Autistic Disorder; Basal	2001
Determining the optimal dose of haloperidol in first-episode psychosis. Journal of psychopharmacology (Oxford, England), 2001, Volume: 15, Issue:4 Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Female; Haloperidol; Humans; Male;	2001
Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia. European archives of psychiatry and clinical neuroscience, 2001, Volume: 251, Issue:5 Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease;	2001
Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. The Journal of clinical psychiatry, 2002, Volume: 63, Issue:5 Topics: Adult; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Brief Psychiatric Rating Scale	2002
Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. The American journal of psychiatry, 2002, Volume: 159, Issue:7 Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Antiparkinson Agents; Antipsychotic Agents	2002
Overview: efficacy and safety of the rapid neuroleptization method with injectable haloperidol. The American journal of psychiatry, 1979, Volume: 136, Issue:3 Topics: Acute Disease; Administration, Oral; Basal Ganglia Diseases; Bipolar Disorder; Clinical Trials as To	1979
[Extrapyamidal side-effects with 1-day dosage of haloperidol (author's transl)]. Arzneimittel-Forschung, 1978, Volume: 28, Issue:9 Topics: Adolescent; Adult; Basal Ganglia Diseases; Clinical Trials as Topic; Double-Blind Method; Female; Ha	1978
[Therapy of acute schizophrenic attacks. High dosage haloperidol therapy compared with a two component treatment]. Fortschritte der Medizin, 1979, Jun-21, Volume: 97, Issue:23 Topics: Anxiety; Attention; Basal Ganglia Diseases; Drug Therapy, Combination; Haloperidol; Humans; Memory;	1979
[The assessment of neuroleptogenic extrapyramidal syndroms in psychopharmacological research (author's transl)]. Pharmakopsychiatrie, Neuro-Psychopharmakologie, 1975, Volume: 8, Issue:1 Topics: Adult; Basal Ganglia Diseases; Clinical Trials as Topic; Dibenzoxazepines; Female; Haloperidol; Huma	1975
[Trial of interruption of antiparkinson drugs in long term treatments with neuroleptics]. L'Encephale, 1975, Volume: 1, Issue:1 Topics: Adult; Antiparkinson Agents; Basal Ganglia Diseases; Chlorpromazine; Clinical Trials as Topic; Fluph	1975
Haloperidol in psychiatry. The Medical letter on drugs and therapeutics, 1975, Jan-31, Volume: 17, Issue:3 Topics: Anxiety Disorders; Basal Ganglia Diseases; Clinical Trials as Topic; Dopamine Antagonists; Fluphenaz	1975
Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients. Psychopharmacologia, 1975, Volume: 40, Issue:4 Topics: Adult; Aged; Basal Ganglia Diseases; Clinical Trials as Topic; Clozapine; Dibenzazepines; Haloperido	1975
A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Theoretical implications for potency differences among neuroleptics. Psychopharmacologia, 1975, Aug-21, Volume: 43, Issue:2 Topics: Adult; Affect; Anxiety; Basal Ganglia Diseases; Benztropine; Chlorpromazine; Clinical Trials as Topi	1975
[A double-blind study of metoclopramide in the treatment of schizophrenia and determination of prolactin]. Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry, 1992, Volume: 25, Issue:6 Topics: Adolescent; Adult; Basal Ganglia Diseases; Double-Blind Method; Female; Haloperidol; Humans; Male; M	1992
Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo. Clinical neuropharmacology, 1991, Volume: 14 Suppl 2 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Dys	1991
A double-blind comparative multicentre study of controlled-release remoxipride, immediate-release remoxipride and haloperidol in schizophrenia. Pharmacopsychiatry, 1991, Volume: 24, Issue:5 Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Delayed-Action Preparat	1991
Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Archives of general psychiatry, 1991, Volume: 48, Issue:8 Topics: Acute Disease; Adolescent; Adult; Basal Ganglia Diseases; Double-Blind Method; Drug Administration S	1991
Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study. Pharmacopsychiatry, 1990, Volume: 23, Issue:3 Topics: Adult; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Female; Halop	1990
A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders. Acta psychiatrica Scandinavica. Supplementum, 1990, Volume: 358 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Double-Blind Method; Female;	1990
A double-blind multicentre study comparing remoxipride, controlled release formulation, with haloperidol in schizophrenia. Acta psychiatrica Scandinavica. Supplementum, 1990, Volume: 358 Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; De	1990
Safety evaluation in both short- and long-term treatment of schizophrenia with remoxipride. Acta psychiatrica Scandinavica. Supplementum, 1990, Volume: 358 Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Dose-Response Relationship, Drug; D	1990
Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ (Clinical research ed.), 1990, Oct-13, Volume: 301, Issue:6756 Topics: Administration, Oral; Basal Ganglia Diseases; Double-Blind Method; Drug Evaluation; Evaluation Studi	1990
Differential effects of a new dibenzo-epine neuroleptic compared with haloperidol. Results of an open and crossover study. Pharmacopsychiatry, 1987, Volume: 20, Issue:4 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Depression; Dibenzazepines; F	1987
The use of benzodiazepines in the treatment of manic-depressive illness. The Journal of clinical psychiatry, 1988, Volume: 49 Suppl Topics: Acute Disease; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Basal Ga	1988
Pharmacological study in Meige's syndrome with predominant blepharospasm. Clinical neuropharmacology, 1988, Volume: 11, Issue:1 Topics: Aged; Basal Ganglia Diseases; Blepharospasm; Clinical Trials as Topic; Clonazepam; Double-Blind Meth	1988
Haloperidol versus thioridazine in the treatment of behavioral symptoms in senile dementia of the Alzheimer's type: preliminary findings. The Journal of clinical psychiatry, 1986, Volume: 47, Issue:6 Topics: Aged; Alzheimer Disease; Basal Ganglia Diseases; Drug Evaluation; Fatigue; Female; Haloperidol; Huma	1986
Review of clinical and laboratory experiences with molindone hydrochloride. The Journal of clinical psychiatry, 1985, Volume: 46, Issue:8 Pt 2 Topics: Akathisia, Drug-Induced; Basal Ganglia Diseases; Clinical Trials as Topic; Dose-Response Relationshi	1985
A crossover study of clocapramine and haloperidol in chronic schizophrenia. The Journal of international medical research, 1985, Volume: 13, Issue:6 Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Basal Ganglia Diseases; Chronic Disease; D	1985
Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate. Archives of general psychiatry, 1972, Volume: 27, Issue:1 Topics: Adult; Aged; Basal Ganglia Diseases; Brain Chemistry; Clinical Trials as Topic; Dopamine; Evaluation	1972
Comparison of injectable haloperidol and chlorpromazine. The American journal of psychiatry, 1972, Volume: 129, Issue:1 Topics: Acute Disease; Adult; Age Factors; Aged; Basal Ganglia Diseases; Chlorpromazine; Clinical Trials as	1972
Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. The American journal of psychiatry, 1973, Volume: 130, Issue:4 Topics: Adult; Basal Ganglia Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Evaluatio	1973
A quantitative study of neuroleptic-induced extrapyramidal symptoms and their response to dexetimide, a potent and long-acting antiparkinsonian agent. Acta psychiatrica Scandinavica, 1971, Volume: 47, Issue:4 Topics: Administration, Oral; Adult; Antiparkinson Agents; Basal Ganglia Diseases; Benztropine; Benzyl Compo	1971

haloperidol and Basal Ganglia Diseases